longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Ascendis Pharmac

ASND

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 17.41, above the reasonable range, cheaper than 13.03% of the time in the past 3 years, and the industry ranks 36/602, the industry Median -2.15.

17.41xP/E
$227.87Stock price
$13.09Earnings per share
17.41xP/E
Stock price$227.87Earnings per share$13.09

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-16.36x
Typical range
-40.50x–-9.62x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
24.92x11.27%$217.90B
VRTXUSVertex Pharma
29.04x36.48%$127.93B
REGNUSRegeneron Pharma
17.49x5.79%$75.69B
UTHRUSUnited Therap
17.72x6.39%$23.23B
GMABUSGenmab A/S
27.12x24.38%$21.37B
ASNDUSAscendis Pharmac
17.41x473.98%$14.99B
NBIXUSNeurocrine Biosciences
20.63x50.69%$14.55B
EXELUSExelixis
16.81x16.46%$14.47B
TGTXUSTG Therap
18.82x64.86%$8.31B
PBYIUSPuma BioTech
18.37x37.70%$490.91M
KMDAUSKamada
21.55x36.43%$479.57M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.